<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385214</url>
  </required_header>
  <id_info>
    <org_study_id>03.12</org_study_id>
    <nct_id>NCT02385214</nct_id>
    <nct_alias>NCT01457157</nct_alias>
  </id_info>
  <brief_title>MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma</brief_title>
  <acronym>MelMarT</acronym>
  <official_title>A Phase III, Multi-centre, Multi-national Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melanoma and Skin Cancer Trials Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peter MacCallum Cancer Centre, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norfolk and Norwich University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Melanoma and Skin Cancer Trials Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with a primary invasive melanoma are recommended to undergo excision of the primary&#xD;
      lesion with a wide margin. There is evidence that less radical margins of excision may be&#xD;
      just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of&#xD;
      the primary lesion for adult patients with a primary invasive cutaneous melanomas &gt;=1mm thick&#xD;
      to determine differences in the rate of local recurrence and melanoma specific survival. A&#xD;
      reduction in margins is expected to improve quality of life in patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine whether there is a difference in local recurrence rates and&#xD;
      melanoma survival rates for patients treated with either a 1cm excision margin or 2cm margin&#xD;
      for both intermediate &amp; high risk melanomas. The study is designed to be able to prove or&#xD;
      disprove that there is no difference in risk of the tumour recurring around the scar or&#xD;
      anywhere else in the body between the two groups of patients. This study is designed to show&#xD;
      that the risk of long-term pain associated with surgery can be halved. If the study shows no&#xD;
      risk of the tumour recurrence then we will also be able to determine how much of an impact&#xD;
      the narrower excision has on patients in terms of improved quality of life and reduced side&#xD;
      effects from the surgery and melanoma disease. This trial will also evaluate and determine&#xD;
      the economic impact of narrower excision margins on the health services and society in&#xD;
      general.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 3, 2015</start_date>
  <completion_date type="Anticipated">August 5, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Melanoma Recurrence (Melanoma Specific Survival)</measure>
    <time_frame>0-120 months</time_frame>
    <description>Time from randomisation to clinically, histologically or radiologically confirmed local recurrence of melanoma including satellite lesions and in transit metastases to regional draining lymph nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-Free Survival</measure>
    <time_frame>0-120 months</time_frame>
    <description>Time from randomisation to any clinical, histological or radiologically confirmed melanoma recurrence or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL and neuropathic pain assessments Neuropathic Pain (PainDetect)</measure>
    <time_frame>Baseline, 3, 6 12, 24 &amp; 60 months.</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>0-120 Months</time_frame>
    <description>Time from randomisation to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Within 1 year</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a participant administered a treatment which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavourable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the treatment timing, whether or not considered related to the treatment. An AE is any adverse change (developing or worsening) from the participant's pre-treatment condition, including intercurrent illness.&#xD;
AEs and any pre-existing medical conditions will be recorded at the Baseline assessment and routinely at Follow Up, until the participant completes the study, withdraws or dies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery related adverse events</measure>
    <time_frame>Up to 30 days from randomisation</time_frame>
    <description>The following surgical adverse events will be recorded from the time of trial treatment to 30 days following the wide excision (inclusive):&#xD;
wound separation&#xD;
seroma/haematoma at wide local excision site&#xD;
haemorrhage&#xD;
infection&#xD;
skin graft failure&#xD;
necrosis of flap used for reconstruction&#xD;
deep venous thrombosis&#xD;
urinary tract infection&#xD;
pneumonia&#xD;
cardiac complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health System Resource Use</measure>
    <time_frame>Baseline, 3, 6, 12, 24 and 60 months</time_frame>
    <description>All hospitalisations and other interventions will be captured in order to measure resource use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Cutaneous Melanoma by AJCC V7 Stage</condition>
  <arm_group>
    <arm_group_label>Arm A Wide Local Excision = 1cm Margin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM A: Experimental Arm Wide Local Excision = 1cm Margin + Sentinel Lymph Node Biopsy&#xD;
+/- Reconstruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Wide Local Excision = 2cm Margin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM B:Control Arm Wide Local Excision = 2cm Margin + Sentinel Lymph Node Biopsy&#xD;
+/- Reconstruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wide Local Excision = 1cm Margin</intervention_name>
    <description>A wide local excision involves removing an extra &quot;safety margin&quot; of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.</description>
    <arm_group_label>Arm A Wide Local Excision = 1cm Margin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wide Local Excision = 2cm Margin</intervention_name>
    <description>A wide local excision involves removing an extra &quot;safety margin&quot; of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.</description>
    <arm_group_label>Arm B Wide Local Excision = 2cm Margin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have a primary invasive cutaneous melanoma of Breslow thickness greater&#xD;
             than 1 millimetre as determined by diagnostic biopsy (narrow excision, incision or&#xD;
             punch biopsy) and subsequent histopathological analysis.&#xD;
&#xD;
          2. Patients must have had the invasive primary completely excised, including any in situ&#xD;
             component but excluding melanocytic atypia, with a narrow margin, either in one stage&#xD;
             or more than one stage in the case where an incision or punch biopsy has previously&#xD;
             been performed. This information, including measured margins of lateral and deep&#xD;
             clearance must be documented on the pathology report.&#xD;
&#xD;
          3. Must have a primary melanoma that is cutaneous (including head, neck, trunk,&#xD;
             extremity, scalp, palm, sole).&#xD;
&#xD;
          4. An uninterrupted 2cm margin must be technically feasible around biopsy scar or primary&#xD;
             melanoma.&#xD;
&#xD;
          5. Randomisation and the primary study intervention, including staging sentinel node&#xD;
             biopsy, must be completed by 120 days of original diagnosis.&#xD;
&#xD;
          6. Patients must be 18 years or older at time of consent.&#xD;
&#xD;
          7. Patient must be able to give informed consent and comply with the treatment protocol&#xD;
             and follow-up plan.&#xD;
&#xD;
          8. Life expectancy of at least 10 years from the time of diagnosis, not considering the&#xD;
             melanoma in question, as determined by the PI.&#xD;
&#xD;
          9. Patients must have an ECOG performance score between 0 and 1.&#xD;
&#xD;
         10. A survivor of prior cancer is eligible provided that ALL of the following criteria are&#xD;
             met and documented:&#xD;
&#xD;
               -  The patient has undergone potentially curative therapy for all prior&#xD;
                  malignancies,&#xD;
&#xD;
               -  There has been no evidence of recurrence of any prior malignancies for at least&#xD;
                  FIVE years (except for successfully treated cervical or non-melanoma skin cancer&#xD;
                  with no evidence of recurrence), and&#xD;
&#xD;
               -  The patient is deemed by their treating physician to be at low risk of recurrence&#xD;
                  from previous malignancies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncertain diagnosis of melanoma i.e. so-called 'melanocytic lesion of unknown&#xD;
             malignant potential'.&#xD;
&#xD;
          2. Patient has already undergone wide local excision at the site of the primary index&#xD;
             lesion.&#xD;
&#xD;
          3. Patient unable or ineligible to undergo staging sentinel lymph node biopsy of the&#xD;
             primary index lesion.&#xD;
&#xD;
          4. Desmoplastic or neurotropic melanoma.&#xD;
&#xD;
          5. Microsatellitosis as per AJCC 2009 definition&#xD;
&#xD;
          6. Subungual melanoma&#xD;
&#xD;
          7. Patient has already undergone a local flap reconstruction of the defect after excision&#xD;
             of the primary and determination of an accurate excision margin is impossible.&#xD;
&#xD;
          8. History of previous or concurrent (i.e., second primary) invasive melanoma.&#xD;
&#xD;
          9. Melanoma located distal to the metacarpophalangeal joint, on the tip of the nose, the&#xD;
             eyelids or on the ear, mucous membranes or internal viscera.&#xD;
&#xD;
         10. Physical, clinical, radiographic or pathologic evidence of satellite, in-transit,&#xD;
             regional, or distant metastatic melanoma.&#xD;
&#xD;
         11. Patient has undergone surgery on a separate occasion to clear the lymph nodes of the&#xD;
             probable draining lymphatic field, including sentinel lymph node biopsy, of the index&#xD;
             melanoma.&#xD;
&#xD;
         12. Any additional solid tumour or hematologic malignancy during the past 5 years except&#xD;
             T1 skin lesions of squamous cell carcinoma, basal cell carcinoma, or uterine/cervical&#xD;
             cancer.&#xD;
&#xD;
         13. Melanoma-related operative procedures not corresponding to criteria described in the&#xD;
             protocol.&#xD;
&#xD;
         14. Planned adjuvant radiotherapy to the primary melanoma site after Wide Local Excision&#xD;
             is not permitted as part of the protocol and any patients given this treatment would&#xD;
             be excluded from the study.&#xD;
&#xD;
         15. History of organ transplantation.&#xD;
&#xD;
         16. Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at any&#xD;
             time during study participation or within 6 months prior to enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Moncrieff</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norfolk &amp; Norwich University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Henderson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter MacCallum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia - Poche Centre</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Melanom Clinic</name>
      <address>
        <city>Coolangatta</city>
        <state>Queensland</state>
        <zip>4225</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre Division of Cancer Surgery</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>GÃ¶teborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <state>England</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Essex Hospital Services NHS Trust</name>
      <address>
        <city>Broomfield</city>
        <state>Essex</state>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Helens &amp; Knowsley NHS Trust</name>
      <address>
        <city>St Helens</city>
        <state>Mersyside</state>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Cancer</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

